Suppr超能文献

对抗黏膜黑色素瘤:最新进展与未来展望

Combatting mucosal melanoma: recent advances and future perspectives.

作者信息

Tyrrell Helen, Payne Miranda

机构信息

Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford, Oxford, United Kingdom of Great Britain & Northern Ireland.

出版信息

Melanoma Manag. 2018 Oct 8;5(3):MMT11. doi: 10.2217/mmt-2018-0003. eCollection 2018 Sep.

Abstract

Mucosal melanomas are a rare subtype of melanoma and are associated with a particularly poor prognosis. Due to the rarity of the diagnosis, and the pace with which the management of cutaneous melanoma has evolved over recent years, there is little good evidence to guide management and evidence-based clinical guidelines are still in development in the UK. In this review we provide an overview of the management of mucosal melanoma, highlighting the critical differences between cutaneous and mucosal melanomas, before examining recent advances in the systemic treatment of this disease and likely future directions.

摘要

黏膜黑色素瘤是黑色素瘤的一种罕见亚型,预后特别差。由于该诊断罕见,且近年来皮肤黑色素瘤的治疗进展迅速,几乎没有充分的证据来指导治疗,英国仍在制定循证临床指南。在本综述中,我们概述了黏膜黑色素瘤的治疗,强调了皮肤黑色素瘤和黏膜黑色素瘤之间的关键差异,然后探讨了该疾病全身治疗的最新进展以及可能的未来方向。

相似文献

1
Combatting mucosal melanoma: recent advances and future perspectives.
Melanoma Manag. 2018 Oct 8;5(3):MMT11. doi: 10.2217/mmt-2018-0003. eCollection 2018 Sep.
2
Targeted Therapy and Immunotherapy for Melanoma in Japan.
Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8.
4
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
J Clin Oncol. 2017 Jan 10;35(2):226-235. doi: 10.1200/JCO.2016.67.9258. Epub 2016 Nov 7.
6
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.
7
Mucosal Melanoma: a Literature Review.
Curr Oncol Rep. 2018 Mar 23;20(3):28. doi: 10.1007/s11912-018-0675-0.
8
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Front Immunol. 2021 Jun 4;12:680407. doi: 10.3389/fimmu.2021.680407. eCollection 2021.
10
An Update on Mucosal Melanoma: Future Directions.
Acta Dermatovenerol Croat. 2019 Mar;27(1):11-15.

引用本文的文献

1
Capacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma.
Cancers (Basel). 2025 Jul 15;17(14):2357. doi: 10.3390/cancers17142357.
2
Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma.
Case Rep Hematol. 2025 Jul 1;2025:5444075. doi: 10.1155/crh/5444075. eCollection 2025.
3
Capacity for compensatory cyclin D2 response confers trametinib resistance in canine mucosal melanoma.
bioRxiv. 2025 Apr 26:2025.04.24.650512. doi: 10.1101/2025.04.24.650512.
4
Recurrent Malignant Melanoma on the Tongue: A Case Report and Review of the Literature.
Cancer Rep (Hoboken). 2025 May;8(5):e70215. doi: 10.1002/cnr2.70215.
5
Melanocortin-1 receptor expression as a predictive factor for postoperative outcomes in melanoma patients: a retrospective study.
Front Immunol. 2025 Mar 27;16:1570502. doi: 10.3389/fimmu.2025.1570502. eCollection 2025.
6
Malignant Melanoma of the Tongue: A Scoping Review.
Life (Basel). 2025 Jan 28;15(2):191. doi: 10.3390/life15020191.
7
Primary Sinonasal Mucosal Melanoma: A Narrative Review.
Diagnostics (Basel). 2025 Feb 18;15(4):496. doi: 10.3390/diagnostics15040496.
10
A Rare and Rapidly Progressive Case of Primary Esophageal Malignant Melanoma in an Elderly Patient.
Cureus. 2024 Nov 19;16(11):e74056. doi: 10.7759/cureus.74056. eCollection 2024 Nov.

本文引用的文献

1
Immunotherapy in malignant melanoma: recent approaches and new perspectives.
Melanoma Manag. 2017 Mar;4(1):39-48. doi: 10.2217/mmt-2016-0019. Epub 2017 Mar 1.
2
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
Oncotarget. 2017 Aug 3;8(44):78174-78192. doi: 10.18632/oncotarget.19836. eCollection 2017 Sep 29.
3
New perspectives for targeting RAF kinase in human cancer.
Nat Rev Cancer. 2017 Nov;17(11):676-691. doi: 10.1038/nrc.2017.79. Epub 2017 Oct 6.
5
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
6
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
7
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
8
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
Expert Rev Anticancer Ther. 2017 Jul;17(7):647-655. doi: 10.1080/14737140.2017.1341315. Epub 2017 Jun 19.
9
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Cancer. 2017 Jun 1;123(S11):2118-2129. doi: 10.1002/cncr.30435.
10
Whole-genome landscapes of major melanoma subtypes.
Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验